Abstract: The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesicles, and fractions thereof. The present disclosure further provides methods for analyzing activities, and the functionality and potency, of such secretomes, extracellular vesicles, and fractions thereof. The present disclosure also relates to the therapeutic use of secretomes, extracellular vesicles, and fractions thereof. The present disclosure further relates to a good manufacturing practices (GMP)-ready, scalable, culture protocol for the release of clinic-ready secretomes.

Abstract: The present invention relates to a biomaterial for use as medicament intended for the treatment of cardiac tissues, to a process for producing the biomaterial, and also to a biomaterial according to the invention for use as medicament or medical device. The biomaterial of the present invention comprises a biocompatible biodegradable polymer including extracellular vesicles from stem cells. The process of the present invention comprises a step of soaking the biocompatible biodegradable polymer in a biocompatible liquid medium comprising extracellular vesicles from stem cells or from the differentiated derivatives thereof, or a mixing of the biocompatible biodegradable polymer or of the corresponding monomer(s) with extracellular vesicles from stem cells. The biomaterial according to the invention is of use as medicament, especially for the treatment of deficient human or animal cardiac tissue.

Abstract: The present invention relates to an electrospun fully biodegradable vascular valved prosthesis, allowing tissue regeneration and growth potential optionally comprising a bifurcation, preferably T-shaped, a mandrel for electrospinning said vascular valved prosthesis, and a method for electrospinning said vascular valved prosthesis.

Abstract: The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention.

Abstract: The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention.

Abstract: Perfusion and preservation and/or reperfusion solutions for surgery and organ transplantation, including that of the heart, a feature of which solutions is the inclusion of at least one antioxidant compound, such as a trapping agent for free oxygen radicals, in particular glutathione in the reduced state or N-acetylcysteine, said solutions possessing a zero or greatly reduced partial pressure of oxygen which is maintained substantially at this value up to the time of use. The solution is preferably presented in flexible bags impermeable to oxygen.

Abstract: The invention relates to a process of cross-linking collagen. This process is of the type comprising the formation of amide bonds by means of acylazide groups and is characterized in that the collagen is reacted with diphenylphosphorylazide. The process according to the invention makes it possible to simplify the collagen cross-linking process and to adjust the degree of cross-linking at discretion without introducing any cross-linking agent.

Abstract: This process, which essentially comprises the following steps:esterification of the free acid groups of the collagen,transformation of the esterified groups into hydrazides groups,transformation of the hydrazide groups into azide groups by the action of nitrous acid, is characterized in that each step is separated by a rinsing in an aqueous salt solution, and in that the step of transformation of esterified groups into azide groups and the step of transformation of hydrazide groups into azide groups by the action of nitrous acid, are performed in the presence of salt.

Abstract: A coronary sinus catheter having a flexible elongate member with proximal and distal extremities. The flexible elongate member has at least two lumens extending longitudinally thereof. A balloon is mounted on the distal extremity of the flexible elongate member and has its interior in communication with one of the lumens. The balloon has at least one truncated conical surface with outwardly facing spaced apart parallel concentric lands formed thereon for frictionally engaging the coronary sinus to provide a high retentive force for the catheter.